Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin

Journal of Clinical Rheumatology

Volumn 17, Issue 1, 2011, Pages 28-30

  Bouquié, Régis ^a   Deslandes, Guillaume ^b   Renaud, Christian ^b   Dailly, Eric ^a   Haloun, Alain ^b   Jolliet, Pascale ^a  

^a Universite de Nantes   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

chronic renal failure; Colchicine; cyclosporin; P glycoprotein; rhabdomyolysis

Indexed keywords

ALPHA TOCOPHEROL; AZITHROMYCIN; CALCIUM; COLCHICINE; COLECALCIFEROL; COTRIMOXAZOLE; CREATINE KINASE; CYCLOSPORIN; CYCLOSPORIN A; ESOMEPRAZOLE; EVEROLIMUS; FERROUS ASCORBATE; GLYCOPROTEIN P; HYDROCORTISONE; IRBESARTAN; LYSINE ACETYLSALICYLATE; MYOGLOBIN; NEOMYCIN; NICORANDIL; PANCREATIN; PRAVASTATIN;

ADULT; ARTICLE; BRONCHIOLITIS; CASE REPORT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; GOUT; HEART LUNG TRANSPLANTATION; HUMAN; LONG TERM CARE; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHABDOMYOLYSIS;

ADULT; ANTI-BACTERIAL AGENTS; ANTICHOLESTEREMIC AGENTS; AZITHROMYCIN; COLCHICINE; CYCLOSPORINE; CYSTIC FIBROSIS; DRUG INTERACTIONS; GOUT; GOUT SUPPRESSANTS; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MULTIPLE ORGAN FAILURE; P-GLYCOPROTEIN; PRAVASTATIN; RHABDOMYOLYSIS;

EID: 78651367718     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3182056042     Document Type: Article

References (16)

1. Niel E, Scherrmann J. Colchicine today. Joint Bone Spine. 2006;73:672-678.
2. Eleftheriou G, Bacis G, Fiocchi R, et al. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila). 2008;46:827-830.
3. Dixon AJ, Wall GC Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother. 2001;35: 192-195.
4. Asakura E, Nakayama H, Sugie M, et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur JPharmacol. 2004;484:333-339.
5. Goldberg H, Ling V, Wong PY, et al. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 1988;152:552-558.
6. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266-268.
7. McKinnell J, Tayek JA. Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis. J Clin Rheumatol. 2009;15:303-305.
8. Chen Y, Huang S, Liu C, et al. Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. Int J Pharm. 2008;350:230-239.
9. Baud FJ, Sabouraud A, Vicaut E, et al. Treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med. 1995;332:642-645.
10. Terkeltaub RA, Furst DE, Bennett K, et al. High-vs low-dosing of oral colchicine for early acute gout flare: twenty-four hour outcome results of the first randomized, placebo-controlled, dose comparison colchicine trial. Arthritis Rheum. 2010;62:1060-1068.
11. Le Bellec M, de la Gastine B, Mosquet B, et al. Colchicine intoxication in four elderly patients: how to prevent it? Rev Med Interne. 2009;30:783-788.
12. Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009;11:236.
13. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use oforal prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371: 1854-1860.
14. Antman EM, Bennett JS, Daugherty A, et al. Use ofnonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
15. Janssens HJEM, Lucassen PLBJ, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008:CD005521.
16. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.